{"schema_version":"secwatch.filing_event.v1","accession":"0001237831-25-000029","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.990529+00:00","generated_at":"2026-05-16T23:23:19.849952+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Globus Medical Q3 revenue $769M (+23% YoY); raises FY2025 EPS guidance to $3.75-$3.85","bullets":["Net sales $769.0M, +22.9% YoY; base business (ex-Nevro) $669.8M (+7.0%); Nevro contributed $99.3M.","GAAP diluted EPS $0.88, up 134% YoY; non-GAAP diluted EPS $1.18, up 42.6% YoY.","FY2025 revenue guidance raised to $2.86-$2.90B; non-GAAP EPS raised to $3.75-$3.85 (prev $3.00-$3.30).","Record non-GAAP free cash flow of $213.9M in Q3; share repurchases of $40M in Q3, total $255.5M YTD.","Nevro acquisition now expected to be accretive to earnings in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001237831-25-000029","json":"https://secwatch.observer/filing/0001237831-25-000029.json","markdown":"https://secwatch.observer/filing/0001237831-25-000029.md","text":"https://secwatch.observer/filing/0001237831-25-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000123783125000029/0001237831-25-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000123783125000029/gmed-20251106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:23:19.849952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}